Since increased VEGF levels correlates with tumor aggressiveness, metastatic potential and relapse, inhibition of the VEGF signaling pathway, either by blocking the extracellular bindings of VEGF to its receptor (antibodies to VEGF or extracellular domains of VEGF receptors) or by inhibiting the activation of VEGFRs (receptor tyrosine kinase inhibitors, a.k.a RTK inhibitors), has become an established therapy for the treatment of many types of tumors in the clinic [2]. Here, VEGFA is linked to neoplasm.